Lane 1: Raji
Lane 2: MCF-2
Lane 3: A549
Lane 4: Human kidney
Rabbit polyclonal primary
TGF-Beta 1 Antibody (ER31210)
Synthetic peptide within human tgf-beta 1 c-terminal.
Raji, MCF-7, A549, human kidney tissue, mouse kidney tissue, SKBR-3, Hela, HepG2
Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.
1*PBS (pH7.4), 0.2% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Peptide affinity purified
Cartilage-inducing factor antibody; CED antibody; Differentiation inhibiting factor antibody; DPD1 antibody; LAP antibody; Latency-associated peptide antibody; Prepro transforming growth factor beta 1 antibody; TGF beta 1 antibody; TGF beta antibody; TGF beta 1 protein antibody; TGF-beta 1 protein antibody; TGF-beta-1 antibody; TGF-beta-5 antibody; TGF-beta1 antibody; TGFB antibody; Tgfb-1 antibody; tgfb1 antibody; TGFB1_HUMAN antibody; TGFbeta antibody; TGFbeta1 antibody; Transforming Growth Factor b1 antibody; Transforming Growth Factor beta 1 antibody; Transforming growth factor beta 1a antibody; transforming growth factor beta-1 antibody; transforming growth factor, beta 1 antibody; Transforming Growth Factor-ß1 antibody
Belongs to the TGF-beta family.
Highly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Colocalizes with ASPN in chondrocytes within OA lesions of articular cartilage.
Transforming growth factor beta-1 proprotein: The precursor proprotein is cleaved in the Golgi apparatus by FURIN to form Transforming growth factor beta-1 (TGF-beta-1) and Latency-associated peptide (LAP) chains, which remain non-covalently linked, rendering TGF-beta-1 inactive.; [Latency-associated peptide]: N-glycosylated. Deglycosylation leads to activation of Transforming growth factor beta-1 (TGF-beta-1); mechanisms triggering deglycosylation-driven activation of TGF-beta-1 are however unclear.
Transforming growth factor beta-1: Multifunctional protein that regulates the growth and differentiation of various cell types and is involved in various processes, such as normal development, immune function, microglia function and responses to neurodegeneration (By similarity). Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains remain non-covalently linked rendering TGF-beta-1 inactive during storage in extracellular matrix. At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1, LRRC32/GARP and LRRC33/NRROS that control activation of TGF-beta-1 and maintain it in a latent state during storage in extracellular milieus. TGF-beta-1 is released from LAP by integrins (ITGAV:ITGB6 or ITGAV:ITGB8): integrin-binding to LAP stabilizes an alternative conformation of the LAP bowtie tail and results in distortion of the LAP chain and subsequent release of the active TGF-beta-1. Once activated following release of LAP, TGF-beta-1 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal (PubMed:20207738).